Journal article
Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine
Daniel Cowley, Daniel Pavlic, Nada Bogdanovic-Sakran, Karen Boniface, Carl D Kirkwood, Julie E Bines
HUMAN VACCINES & IMMUNOTHERAPEUTICS | TAYLOR & FRANCIS INC | Published : 2018
Grants
Awarded by Bill and Melinda Gates Foundation
Awarded by Australian National Health and Medical Research Council
Awarded by New Zealand Health Research Council International Investment Opportunities Fund Trans- Tasman Clinical Trials Collaborative Initiative
Funding Acknowledgements
This study was funded by an investigator driven grant from the Bill and Melinda Gates Foundation (OPP1127967). The Phase IIa clinical trial of RV3-BB was supported by the Australian National Health and Medical Research Council through a project grant (ID491239) and the New Zealand Health Research Council International Investment Opportunities Fund Trans- Tasman Clinical Trials Collaborative Initiative (08_T02). This research was also supported by the Victorian Government's Operational Infrastructure Support Program.